Contact Us
Drug Search Results
More Filters [+]

JS-014

Alternative Names: js-014, js 014, js014
Latest Update: 2022-11-23
Latest Update Note: Clinical Trial Update

Product Description

JS014, a Recombinant Fusion Protein of Interleukin-21 and Humanized Anti-human Serum Albumin VHH Antibody, is used in patients with advanced cancer (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05296772)

Mechanisms of Action: IL21 Antagonist,Albumin Antagonist

Novel Mechanism: Yes

Modality: Fusion Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Anwita Biosciences
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for JS-014

Countries in Clinic: Taiwan

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
AWT-EXK21-001

P1

Recruiting

Lymphoma

2024-06-01

44%

Recent News Events

Date

Type

Title

06/28/2021

News Article

 Junshi Biosciences Announces NMPA Acceptance of Investigational New Drug Application for JS014

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions